Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian D Davis

Showing results (211-220 of 282) with videos related to

Pageof 29
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigenAndrew M Scott, Niall Tebbutt, Fook-Thean Lee, et al.
European Urology|October 25, 2016
Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic CategoryIan D Davis, Wanling Xie, Carmel Pezaro, et al.
The Lancet. Oncology|February 22, 2014
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trialRobert J Motzer, Camillo Porta, Nicholas J Vogelzang, et al.
Journal of Surgical Oncology|May 24, 2018
Predictors of new-onset chronic kidney disease in patients managed surgically for T1a renal cell carcinoma: An Australian population-based analysisThomas Ahn, Robert J Ellis, Victoria M White, et al.
European Urology|October 22, 2022
Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database ConsortiumZiad Bakouny, Talal El Zarif, Shaan Dudani, et al.
Clinical Genitourinary Cancer|January 8, 2026
Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC)Audreylie Lemelin, Martin Zarba, Kosuke Takemura, et al.
Clinical Genitourinary Cancer|June 23, 2026
Pembrolizumab and Denosumab in Clear-Cell Renal-Cell CarcinomaCarole A Harris, Danka S Zebic, Michelle F Morris, et al.
BJU International|July 17, 2021
'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501)Dickon Hayne, Jeremy Grummet, David Espinoza, et al.
BJU International|November 21, 2023
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinomaCiara Conduit, Ian D Davis, Jeffrey C Goh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Phase I trial of 131I-huA33 in patients with advanced colorectal carcinomaGeoffrey Chong, Fook Thean Lee, Wendie Hopkins, et al.
Pageof 29

Showing results (211-220 of 282) with videos related to

Sort By:
Pageof 29
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigenAndrew M Scott, Niall Tebbutt, Fook-Thean Lee, et al.
European Urology|October 25, 2016
Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic CategoryIan D Davis, Wanling Xie, Carmel Pezaro, et al.
The Lancet. Oncology|February 22, 2014
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trialRobert J Motzer, Camillo Porta, Nicholas J Vogelzang, et al.
Journal of Surgical Oncology|May 24, 2018
Predictors of new-onset chronic kidney disease in patients managed surgically for T1a renal cell carcinoma: An Australian population-based analysisThomas Ahn, Robert J Ellis, Victoria M White, et al.
European Urology|October 22, 2022
Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database ConsortiumZiad Bakouny, Talal El Zarif, Shaan Dudani, et al.
Clinical Genitourinary Cancer|January 8, 2026
Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC)Audreylie Lemelin, Martin Zarba, Kosuke Takemura, et al.
Clinical Genitourinary Cancer|June 23, 2026
Pembrolizumab and Denosumab in Clear-Cell Renal-Cell CarcinomaCarole A Harris, Danka S Zebic, Michelle F Morris, et al.
BJU International|July 17, 2021
'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501)Dickon Hayne, Jeremy Grummet, David Espinoza, et al.
BJU International|November 21, 2023
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinomaCiara Conduit, Ian D Davis, Jeffrey C Goh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Phase I trial of 131I-huA33 in patients with advanced colorectal carcinomaGeoffrey Chong, Fook Thean Lee, Wendie Hopkins, et al.
Pageof 29